119963-50-7

Usage

Uses

Used in Pharmaceutical Industry:
Dehydrotanshinone II A is used as a potential anticancer agent for its significant cytotoxic effects against various cancer cell lines. It may contribute to the development of new anticancer drugs due to its ability to target and reduce tumor growth.
Used in Anti-inflammatory Applications:
Dehydrotanshinone II A is utilized as an anti-inflammatory agent due to its capacity to reduce inflammation, which may have therapeutic applications in the treatment of various inflammatory diseases and conditions.
Used in Antioxidant Applications:
dehydrotanshinone II A is employed as an antioxidant, helping to mitigate oxidative stress. Its antioxidant properties suggest potential health benefits in conditions where oxidative stress plays a role, such as in neurodegenerative diseases or aging-related disorders.
Overall, dehydrotanshinone II A's multifaceted pharmacological profile positions it as a valuable compound for potential applications across various health and medical sectors.

InChI:InChI=1/C19H16O3/c1-10-9-22-18-12-6-7-13-11(5-4-8-19(13,2)3)15(12)17(21)16(20)14(10)18/h4-7,9H,8H2,1-3H3

Upstream product

• 18887-18-8 1-hydroxytanshinone IIA 
• 568-72-9 tanshinone-IIA 

Relevant academic research and scientific papers

Site-selective Csp3-H aryloxylation of natural product Tanshinone IIA and its analogues

A novel catalyst-free Csp3-H aryloxylation approach allowing for rapid installation of a wide range of aryloxyl groups regioselectively at the C-4 position of Tanshinone IIA under simple and mild conditions was developed. This unique protocol exhibited atom-/step-economy, low cost, high efficiency and robust functional-group tolerance, which will greatly facilitate to diversify the A-ring of the bioactive natural product.

Discovery of indoleamine 2,3-dioxygenase 1 (IDO-1) inhibitors based on ortho-naphthaquinone-containing natural product

There is great interest in developing small molecules agents capable of reversing tumor immune escape to restore the body’s immune system. As an immunosuppressive enzyme, indoleamine 2,3-dioxygenase 1 (IDO-1) is considered a promising target for oncology immunotherapy. Currently, none of IDO-1 inhibitors have been launched for clinical practice yet. Thus, the discovery of new IDO-1 inhibitors is still in great demand. Herein, a series of diverse ortho-naphthaquinone containing natural product derivatives were synthesized as novel IDO-1 inhibitors. Among them, 1-ene-3-ketone-17-hydroxyl derivative 12 exhibited significantly improved enzymatic and cellular inhibitory activity against IDO-1 when compared to initial lead compounds. Besides, the molecular docking study disclosed that the two most potent compounds 11 and 12 have more interactions within the binding pocket of IDO-1 via hydrogen-bonding, which may account for their higher IDO-1 inhibitory activity.

Tanshinone IIA derivative with IDO/TDO doubly-selective inhibitory activity

The invention discloses tanshinone IIA derivatives, or their pharmaceutically acceptable salts, prodrugs, hydrates or solvates, a pharmaceutical composition with the tanshinone IIA derivative acting as an active ingredient, and application of the tanshinone IIA derivative in the preparation of drugs to treat tumors with IDO (indoleamine 2,3-dioxygenase) or TDO (tryptophan 2,3-dioxygenase) overexpression or evidently enhanced activity, such as glioblastoma multiforme, mesothelioma, head and neck cancer, non-small cell lung cancer, bladder cancer and breast cancer, and metabolic disorders, suchobesity, and also provides a preparation method of compounds 1 to 9. Enzymatic activity inhibition experiments prove that the compounds 1-16 can evidently inhibit IDO and TDO, and is suitable for thepreparation of drugs to treat IDO- or ITO-mediated diseases.